Succeeding in today’s crowded healthcare market often requires that associations align with like-minded organizations to achieve their goals. It is this realization that has led to a strategic partnership between The Lynx Group and the National Association of Specialty Pharmacy (NASP).
Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business.
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
New York – February 12, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib).
Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®
The FDA recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).
PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform
Onco360 Expected to Rapidly Grow Revenues Over the Next Several Years
MedImpact Healthcare Systems, Inc. and Onco360 today announced a joint collaboration focused on offering MedImpact clients a unique and effective solution for bending the cost curve and delivering quality and value-based Oncology pharmaceutical care.
Results 1 - 6 of 6